Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EWEBNASDAQ:KOIDNASDAQ:NZUSNASDAQ:XDNA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWEBGlobal X Emerging Markets Internet & E-commerce ETF$21.14$21.14$18.42▼$25.54$2.54M0.42469 shsN/AKOIDKraneShares Global Humanoid and Embodied Intelligence Index ETF$24.92-2.0%$0.00$24.92▼$25.96N/AN/A4,145 shs3,672 shsNZUSSPDR MSCI USA Climate Paris Aligned ETF$31.96-0.5%$30.07$26.06▼$34.03$2.56M-1.1512 shs29 shsXDNAKelly CRISPR & Gene Editing Technology ETF$7.38$7.38$5.87▼$11.83$2.21M0.923,034 shsN/AThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWEBGlobal X Emerging Markets Internet & E-commerce ETF0.00%0.00%0.00%0.00%0.00%KOIDKraneShares Global Humanoid and Embodied Intelligence Index ETF-2.04%-1.03%+2,491,999,900.00%+2,491,999,900.00%+2,491,999,900.00%NZUSSPDR MSCI USA Climate Paris Aligned ETF-0.55%+0.14%+1.85%+7.99%+5.35%XDNAKelly CRISPR & Gene Editing Technology ETF0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEWEBGlobal X Emerging Markets Internet & E-commerce ETFN/AN/AN/AN/AN/AN/AN/AN/AKOIDKraneShares Global Humanoid and Embodied Intelligence Index ETFN/AN/AN/AN/AN/AN/AN/AN/ANZUSSPDR MSCI USA Climate Paris Aligned ETFN/AN/AN/AN/AN/AN/AN/AN/AXDNAKelly CRISPR & Gene Editing Technology ETFN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEWEBGlobal X Emerging Markets Internet & E-commerce ETF 2.71Moderate Buy$21.14N/AKOIDKraneShares Global Humanoid and Embodied Intelligence Index ETF 0.00N/AN/AN/ANZUSSPDR MSCI USA Climate Paris Aligned ETF 2.70Moderate Buy$31.96N/AXDNAKelly CRISPR & Gene Editing Technology ETF 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEWEBGlobal X Emerging Markets Internet & E-commerce ETFN/AN/AN/AN/AN/AN/AKOIDKraneShares Global Humanoid and Embodied Intelligence Index ETFN/AN/AN/AN/AN/AN/ANZUSSPDR MSCI USA Climate Paris Aligned ETFN/AN/AN/AN/AN/AN/AXDNAKelly CRISPR & Gene Editing Technology ETFN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEWEBGlobal X Emerging Markets Internet & E-commerce ETFN/AN/A25.72∞N/AN/AN/AN/AN/AKOIDKraneShares Global Humanoid and Embodied Intelligence Index ETFN/AN/A0.00∞N/AN/AN/AN/AN/ANZUSSPDR MSCI USA Climate Paris Aligned ETFN/AN/A28.63∞N/AN/AN/AN/AN/AXDNAKelly CRISPR & Gene Editing Technology ETFN/AN/A17.02∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEWEBGlobal X Emerging Markets Internet & E-commerce ETF$0.060.28%N/AN/AN/AKOIDKraneShares Global Humanoid and Embodied Intelligence Index ETFN/AN/AN/AN/AN/ANZUSSPDR MSCI USA Climate Paris Aligned ETF$1.795.60%N/AN/AN/AXDNAKelly CRISPR & Gene Editing Technology ETFN/A0.12%N/AN/AN/ALatest EWEB, KOID, NZUS, and XDNA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/30/2025NZUSSPDR MSCI USA Climate Paris Aligned ETFQuarterly$0.09681.23%6/2/20256/2/20256/4/2025(Data available from 1/1/2013 forward)Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEWEBGlobal X Emerging Markets Internet & E-commerce ETFN/AKOIDKraneShares Global Humanoid and Embodied Intelligence Index ETFN/ANZUSSPDR MSCI USA Climate Paris Aligned ETFN/AXDNAKelly CRISPR & Gene Editing Technology ETFN/AInsider OwnershipCompanyInsider OwnershipEWEBGlobal X Emerging Markets Internet & E-commerce ETFN/AKOIDKraneShares Global Humanoid and Embodied Intelligence Index ETFN/ANZUSSPDR MSCI USA Climate Paris Aligned ETFN/AXDNAKelly CRISPR & Gene Editing Technology ETFN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEWEBGlobal X Emerging Markets Internet & E-commerce ETFN/A120,000N/ANo DataKOIDKraneShares Global Humanoid and Embodied Intelligence Index ETFN/A2N/AN/ANZUSSPDR MSCI USA Climate Paris Aligned ETFN/A80,000N/AOptionableXDNAKelly CRISPR & Gene Editing Technology ETFN/A300,000N/AOptionableEWEB, KOID, NZUS, and XDNA HeadlinesRecent News About These CompaniesCHOP, Penn advance CRISPR gene editing with fast-developed treatment for an infant with a rare diseaseMay 15, 2025 | msn.comNobel Prize winners convince court to revive CRISPR patent disputeMay 12, 2025 | reuters.comBiotech investors: Stop expecting CRISPR science to make big leapsApril 14, 2025 | statnews.comAI and gene editing promise ‘bespoke proteins’ for biotechOctober 8, 2024 | siliconrepublic.comWeight loss drug breakthroughs, gene therapies, and more: 8 clinical trials to watch right nowOctober 2, 2024 | yahoo.comK-12 Genome Editing at Only $2 a PopSeptember 27, 2024 | yahoo.comVertex Stock: Came For CF Drugs, Staying For Gene TherapyAugust 2, 2024 | seekingalpha.comCRISPR can treat common form of inherited blindness, early data hintMay 15, 2024 | msn.comCRISPR gene editing: in summaryMarch 27, 2024 | biotechniques.comCRISPR Technology Takes Center Stage at SXSW 2024 for the First TimeMarch 9, 2024 | markets.businessinsider.comIntellia Collaborates With ReCode To Develop Gene Therapy For Cystic FibrosisFebruary 15, 2024 | markets.businessinsider.comCRISPR Technology: Unveiling the Breakthrough in Gene Editing and Its Far-Reaching ImplicationsJanuary 18, 2024 | techbullion.comHere's Why CRISPR Therapeutics Stock Rose 54% Last YearJanuary 15, 2024 | msn.comGene editing is now a medical realityDecember 8, 2023 | news.yahoo.comFDA approves first use of CRISPR gene editing to treat sickle cell diseaseDecember 8, 2023 | news.yahoo.comFDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood DisorderDecember 8, 2023 | markets.businessinsider.comGene Editing Will Change Medicine—and Maybe Health Investing TooNovember 24, 2023 | msn.comCRISPR/Cas9 unlocks TuMV resistance in Chinese cabbage: A leap forward in genome-edited plant breedingNovember 24, 2023 | phys.orgIs CRISPR Therapeutics the Best Gene-Editing Stock?November 22, 2023 | msn.comThree people were gene-edited in an effort to cure their HIV. The result is unknown.November 16, 2023 | technologyreview.comMedia Sentiment Over TimeEWEB, KOID, NZUS, and XDNA Company DescriptionsGlobal X Emerging Markets Internet & E-commerce ETF NASDAQ:EWEB$21.14 0.00 (0.00%) As of 06/12/2025The Global X Emerging Markets Internet & E-commerce ETF (EWEB) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks an index of companies positioned to benefit from the advancement of internet and e-commerce technologies in emerging market countries. EWEB was launched on Nov 9, 2020 and is managed by Global X.KraneShares Global Humanoid and Embodied Intelligence Index ETF NASDAQ:KOID$24.92 -0.52 (-2.04%) As of 06/13/2025 02:21 PM EasternKraneShares Trust - KraneShares Asia Robotics and Artificial Intelligence Index ETF is an exchange traded fund launched and managed by Krane Funds Advisors, LLC. The fund invests in public equity markets of Asia/Pacific region. The fund invests in stocks of companies operating across robotics and artificial intelligence sectors. It invests in growth and value stocks of companies across diversified market capitalization. The fund seeks to track the performance of the Solactive Asia Robotics & Artificial Intelligence Index, by using representative sampling technique. KraneShares Trust - KraneShares Asia Robotics and Artificial Intelligence Index ETF is domiciled in the United States.SPDR MSCI USA Climate Paris Aligned ETF NASDAQ:NZUS$31.96 -0.18 (-0.55%) Closing price 06/13/2025 12:56 PM EasternExtended Trading$31.96 +0.00 (+0.00%) As of 06/13/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The SPDR MSCI USA Climate Paris Aligned ETF (NZUS) is an exchange-traded fund that is based on the MSCI USA Climate Paris Aligned index. The fund tracks a tier-weighted index of large- and mid-cap US stocks selected and weighted based on ESG criteria that are compatible with the Paris Climate Agreement and carbon reduction goals. NZUS was launched on Apr 21, 2022 and is managed by State Street.Kelly CRISPR & Gene Editing Technology ETF NASDAQ:XDNA$7.38 0.00 (0.00%) As of 06/12/2025The Strategic CRISPR & Gene Editing Technology ETF (XDNA) is an exchange-traded fund that mostly invests in health care equity. The fund tracks a market-cap-weighted index of companies in developed markets that focus on the advancements in DNA modification technology. XDNA was launched on Jan 12, 2022 and is managed by Kelly. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Fastenal Stock After Split: Poised for 5 More Years of Gains Analysts Love Lovesac, But Investors Should Be Cautious Oracle’s Cloud Boom Is Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
